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Olanzapine (OLZ), a thienobenzodiazepine derivative, is an
antipsychotic drug which is highly effective in the treatment of
schizophrenia and bipolar disorders1,2. It is an atypical
antipsycotic with less extrapyrimidal side effects and greater
positive effects on cognitive deﬁcits than typical antipsycho-
tics3. This is because of its afﬁnity for multiple receptors
including dopamine D2, 5-hydroxytryptamine (5-HT) 2A and
2C, histamine H1, a-adrenergic and muscarinic receptors4.
OLZ has been approved by the US FDA for use as mono-
therapy or in combination with mood stabilizers for the
treatment of acute mania in bipolar disorders1,5. It is available
as coated tablets in dose strengths ranging from 2 to 20 mg
under the brand name Zyprexa and as an orally disintegrating
tablet known as Zyprexa Zydis. Following oral administra-
tion, OLZ is about 93% plasma protein bound, mainly to
albumin and a-acid glycoprotein. It has an oral bioavailability
of about 60% mainly due to hepatic ﬁrst pass metabolism to
the 10-N-glucuronide, 40-N-desmethylolanzapine and olanza-
pine-N-oxide via uridine diphosphate glucuronyltransferase
(UDPGT), cytochrome P450 (CYP) 1A2 and ﬂavin mono-
xygenase (FMO), respectively. After absorption, OLZ reaches
its maximum plasma concentration within 6 h and has a mean
half life of about 33 h6.
Numerous methods are described in the literature to deter-
mine OLZ in different biological ﬂuids including GC with
nitrogen phosphorous7 and mass spectrometric detection8, and
HPLC with electrochemical9–16, ultraviolet17–22, diode array23
and mass spectrometric detection24–37. These methods either
determine OLZ alone9,11,12,14,17,18,20,21,24,25,29,33 or OLZ and its
metabolites10,13,15,16,19,28,37 or OLZ and other drugs particularly
antipsychotics7,8,19,22,23,26,27,30–32,34–36. Of the methods applied
to analysis of human plasma, either the chromatographic run
time was long (45.0 min)9,12,13,15,16,18,20,23,27,35 and the plasma
volume high (Z0.5 mL)9,15,18,20,23,27,29,35 or the method was too
insensitive for routine application. However, the method
reported by Nirogi et al.29 based on liquid chromatography–
tandem mass spectrometry (LC–MS/MS) is highly sensitive with
a lower limit of quantitation (LLOQ) of 100 pg/mL in human
plasma and a demonstrated suitability for application to bioe-
quivalence studies29. Recently, another LC–MS/MS method37
has been applied to the determination of OLZ and N-desmethy-
lolanzapine in human serum and cerebrospinal ﬂuid (CSF) from
patients taking OLZ. The salient features of chromatographic
methods developed for OLZ in human plasma are summarized
in Table 1.
The objective of the present study was to develop and
validate a selective and sensitive method for the estimation of
OLZ in human plasma based on LC–MS/MS. The method
uses quetiapine as internal standard (IS) and has a sensitivityequal to that of Nirogi et al.29 using a smaller plasma volume.
The method is shown to be free of interference from other
antipsychotic drugs commonly taken concomitantly and was
successfully applied to a bioequivalence study of 5 and 10 mg
OLZ tablets in healthy volunteers under fasting and fed
conditions.2. Materials amd methods
2.1. Chemicals and materials
Chemicals and materials (suppliers) were as follows: Reference
standard OLZ (99.5%) (Cadila Healthcare Ltd., Ahmedabad,
India); quetiapine fumarate (IS, 99.2%) (Varda Biotech (P)
Ltd., Mumbai, India); HPLC grade methanol and acetonitrile,
analytical grade ortho-phosphoric acid, ammonia and ammo-
nium formate (S.D. Fine Chemicals Ltd., Mumbai, India);
Oasis HLB extraction cartridges (1 cc, 30 mg) (Waters Cor-
poration, Milford, MA, USA); Control buffered (K2-EDTA)
human plasma stored at 20 1C (Clinical Department, BA
Research India Ltd., Ahmedabad, India); Mettler Toledo AG
XP26DR micro balance (Greifensee, Switzerland); Eppendorf
5810 centrifuge (Hamburg, Germany); deionized water for
LC–MS/MS prepared using a Milli Q water puriﬁcation
system (Millipore, Bangalore, India).
2.2. Instrumentation and conditions
The LC system (Shimadzu, Kyoto, Japan) consisted of an LC-
10ADvp pump, an autosampler (SIL-HTc) and an on-line
degasser (DGU-14A). Separation was performed by isocratic
elution on an ACE 5C18-300 (100 mm 4.6 mm, 5.0 mm) column
(Chromatopak Analytical Instrumentation (India) Pvt. Ltd.,
Mumbai, India) with a mobile phase consisting of acetoni-
trile:0.01% ammonia in 2 mM ammonium formate (85:15, v/v,
pH 6.6) at a ﬂow rate of 0.9 mL/min. The autosampler was
maintained at 4 1C and the injection volume was 5.0 mL.
Ionization and detection of analyte and IS was performed on
an API-4000 triple quadrupole mass spectrometer equipped with
Turbo Ion sprays (MDS SCIEX, Toronto, Canada) operating
in the positive ion mode. Quantitation was performed using
multiple reaction monitoring (MRM) of the protonated pre-
cursor to product ion transitions at m/z 313.2-256.2 for OLZ
and 384.2-253.2 for IS (Figs. 1a and b). All LC and MS
parameters were controlled by Analyst software version 1.4.2.
Optimized source dependant MS parameters were as follows:
Gas 1 (Nebulizer), 55 psi; Gas 2 (heater), 50 psi; ion spray
voltage (ISV), 5500 V; turbo heater temperature (TEM), 550 1C;
entrance potential (EP), 10 V; collision activation dissociation
(CAD), 6 psi; curtain gas (CUR), 30 psi. Compound dependent
Figure 1 Product ion mass spectra of (a) olanzapine (m/z 313.2-256.2) and (b) quetiapine (IS, m/z 384.2-253.2) in positive
ionization mode.
Table 1 Salient features of LC-MS methods developed for olanzapine in human plasma.
No. Extraction procedure (plasma
volume); mean recovery; internal
standard
Column; elution type; mobile phase;
ﬂow rate; injection volume
Detection; maximum on-column loading
at ULOQ per injection volume;
analytical run time; retention time; linear
dynamic range; application
Ref.
1a Liquid–liquid extraction with
2 5 mL of ether in presence of
0.1 mL, 0.1 M NaOH; (0.5 mL);
85.8%; diazepam
Macherry-Nagel C18
(125 mm 2.0 mm, 3 mm); isocratic;
water containing 2.7 mM formic acid
and 10 mM ammonium acetate-
acetonitrile
(53:47, v/v); 0.16 mL/min, 5 mL
LC–MS/MS; 2.5 ng; 10 min; 5.84 min;
1–50 ng/mL; analysis of plasma samples
from 11 schizophrenia patients
administered 10 mg/day olanzapine
27
2 Liquid–liquid extraction with 4 mL of
diethyl ether–dichloromethane in
presence of 50 mL, 0.1 M NaOH;
(0.5 mL); 85.5%; loratadine
Inertsil ODS C18 (100 mm 3.0 mm,
3 mm); isocratic; 10 mM ammonium
acetate buffer-acetonitrile (10:90, v/v);
0.8 mL/min, 10 mL
LC–MS/MS; 0.6 ng; 2.0 min; 1.0 min;
0.1–30 ng/mL; bioequivalence study with
10 mg olanzapine in 18 healthy
volunteers
29
3b Solid phase extraction on 96-well
plate Oasis MCX support; (0.5 mL);
111%; remoxipride
Waters Xbridge C18 (100 mm 2.1 mm,
3.5 mm); gradient; 10 mM ammonium
acetate, pH 8.1 adjusted with 25%
ammonium hydroxide and acetonitrile;
0.3 mL/min, 5 mL
LC–MS; 2 ng; 14 min; 8.1 min;
2–200 ng/mL; analysis of plasma
samples from 177 psychiatric patients
35
4 Solid phase extraction on Oasis HLB
cartridge; (0.2 mL); 94%; quetiapine
ACE 5C18-300 (100 mm 4.6 mm,
5 mm); isocratic; acetonitrile-0.01%
ammonia in 2 mM ammonium formate
(85:15, v/v), pH 7.98; 0.9 mL/min; 5 mL
LC–MS/MS; 0.05 ng; 3.5 min; 2.36 min;
0.1–40 ng/mL; bioequivalence study with
5/10 mg olanzapine orally disintegrating
tablets in 36 healthy Indian males
(18–54 years) having body mass index
between 18.5 and 30.0 kg/height2
PM
aAlong with clozapine, risperidone and quetiapine.
bAlong with aripiprazole, atomoxetine, duloxetine, clozapine, sertindole, venlafaxine and their active metabolites dehydroaripiprazole,
norclozapine, dehydrosertindole and O-desmethylvenlafaxine; PM, present method.
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(CE) and cell exit potential (CXP) were, respectively 70, 35 and
15 V for OLZ and 85, 23 and 12 V for IS. Quadrupole 1 and
quadrupole 3 were maintained at unit resolution and a dwell time
of 600 ms was set for both OLZ and IS.
2.3. Calibration standards and quality control (QC) samples
An OLZ stock solution (100 mg/mL) in methanol was diluted
with methanol:water (80:20, v/v) to produce an intermediatestock solution (800 ng/mL). This was further diluted to prepare
standard and (independently) QC solutions. An IS stock solution
(100 mg/mL) was also prepared in methanol and diluted with
water to give an IS working solution (40.0 ng/mL). All solutions
were stored at 4 1C when not in use. OLZ calibration standards
(CS-1 to CS-10, 0.10, 0.20, 0.50, 1.00, 2.00, 5.00, 10.0, 20.0, 32.0
and 40.0 ng/mL), low (LQC, 0.30 ng/mL), medium (MQC-1,
16.0 ng/mL; MQC-2, 3.00 ng/mL) and high (HQC, 30.0 ng/mL)
QC samples and QC samples at the lower limit of quantitation
(LLOQ QC, 0.10 ng/mL) and upper limit of quantitation (ULOQ
Dinesh Somabhai Patel et al.484QC, 40.0 ng/mL) were prepared by spiking blank plasma with
respective standard solutions (at 5% of the total volume of
plasma). All CS, QC and study samples were stored at 20 1C
pending analysis.2.4. Sample preparation
Plasma samples were thawed, allowed to equilibrate at room
temperature and thoroughly vortexed prior to analysis. Ali-
quots of study samples (190 plus 10 mL methanol:water 80:20,
v/v) or CS and QC samples (200 mL) and 190 mL blank plasma
were transferred into vials to which 15 mL methanol:water
(80:20, v/v) and 200 mL IS working solution were added. After
vortexing, 100 mL 25% orthophosphoric acid solution was
added and the mixture vortexed again. Samples were then
loaded onto SPE cartridges pre-conditioned with 1.0 mL
methanol followed by 1.0 mL water. After centrifugation for
2 min at 1811 g, cartridges were washed with 2 1.0 mL
water and again centrifuged for 1 min at 1811 g. Analyte
and IS were then eluted with 2 0.4 mL acetonitrile:water
(90:10, v/v), centrifuged for 1 min at 1811 g and analyzed by
LC–MS/MS.2.5. Assay validation
Assay validation was carried out according to US FDA
guidelines38. Validation included evaluation of selectivity,
interference, carryover, linearity, precision and accuracy,
reinjection reproducibility, recovery, ion suppression/enhance-
ment, matrix effects, stability and dilution integrity.
Selectivity was assessed by assay of 12 different lots of
blank human plasma (including haemolysed and lipemic
samples) collected with K2-EDTA as anticoagulant. For each
lot, two replicates (190 mL) were spiked with 10 mL methanol:-
water (80:20, v/v) in one case containing IS. (total 24 samples).
In addition, a system suitability sample (SSS) with the same
concentration as CS-2 and two replicates of CS-1 were
prepared. The blank human plasma used for spiking these
samples was chosen from one of the 12 lots. The acceptance
criterion was that at least 90% of samples should be free from
any interference at the retention times of analyte and IS.
Potential interference from acetaminophen, aspirin, caf-
feine, cetirizine, chlorpheniramine maleate, ibuprofen and
pseudoephedrine were evaluated. Additionally, the antipsy-
chotics, clozapine, risperidone and aripiprazole, were studied
for ion suppression/enhancement, analytical recovery
(precision and accuracy) and chromatographic interference
at the MRM transitions of analyte and IS. Their stock
solutions (100 mg/mL) were prepared in methanol and
diluted in methanol:water (80:20, v/v) to 20.0 mg/mL working
solutions. They were then analyzed in triplicate under the
same conditions as the LQC and HQC samples along
with freshly prepared CS and two sets (8 samples) of HQC,
MQC-1, MQC-2 and LQC. The acceptance criteria was that
the accuracy should be in the range 85–115%. MRM transi-
tions (positive ionization mode) for clozapine (327.1/270.2),
risperidone (411.3/191.2) and aripiprazole (448.0/285.2) were
studied.
Carryover was assessed by injecting the following sequence
of samples; double blank plasma, two LLOQ samples, doubleblank plasma, an ULOQ sample, double blank plasma, an
ULOQ sample and ﬁnally double blank plasma.
Linearity was determined by construction of six calibration
curves based on peak area ratios at ten non-zero concentra-
tions. Each calibration curve was analyzed individually by
least squares weighted (1/x2) linear regression. A correlation
coefﬁcient (r2)40.99 was desirable for all calibration curves.
The lowest standard on the calibration curve was accepted as
the LLOQ if the analyte response was at least 10 times more
than that of blank plasma.
To determine intra-day accuracy and precision, a calibra-
tion curve and six replicates of LLOQ QC, LQC, MQC-2,
MQC-1, HQC and ULOQ QC were analysed on the same day.
Inter-day accuracy and precision were assessed by analyzing
three batches of samples on three consecutive days. The
deviation from the nominal concentration is required to be
o715% except at the LLOQ where 720% is allowed.
Similarly, accuracy should be within 715% except at the
LLOQ where it can be within 720% of nominal concentra-
tions. Reinjection reproducibility was performed by reinjecting
one complete validation batch.
Relative recovery (RE), matrix effects (ME) and process
efﬁciency were assessed as recommended by Matuszewski
et al.39. All three parameters were evaluated by assay of six
replicates of HQC, MQC-1, MQC-2 and LQC samples. RE
was calculated by comparing the mean area responses of
samples spiked before extraction with those of samples spiked
after extraction at each QC level. The recovery of IS was
estimated in the same way. Absolute ME were assessed by
comparing the mean area responses of samples spiked after
extraction with those of standard solutions in mobile phase.
Overall ‘‘process efﬁciency’’ (PE, %) was calculated as
(MERE)/100. In addition, the effect of the plasma matrix
was checked using eight different lots of K2-EDTA antic-
oagulated plasma including haemolysed and lipemic samples.
For each lot, four samples at LQC and HQC levels were
spiked after extraction and checked for accuracy and preci-
sion. The effect of the matrix on ion suppression was
evaluated by post-column infusion40 at 5.0 mL/min of a
standard solution containing 16.0 ng/mL OLZ and 40.0 ng/
mL IS in mobile phase via a ‘T’ connector employing a
Harvard infusion pump (Harvard Bioscience, USA). Aliquots
(5.0 mL) of extracted blank plasma (without OLZ and IS) were
then injected and chromatograms acquired. Any reduction in
the baseline on injection of the blank plasma was taken to
indicate ion suppression whereas a peak at the retention time
of either OLZ or IS ws taken to indicate ion enhancement.
Stability was evaluated by comparing concentrations of LQC
and HQC samples subjected to various conditions with those of
freshly prepared samples. Samples were considered stable if
deviation from nominal values waso710.0%. Stock solutions
of OLZ and IS were checked for short term stability at room
temperature and long term stability at 4 1C. Bench top stability,
processed sample stability at room temperature and at 4 1C,
freeze–thaw stability and long term stability at 20 1C were
performed by assay of six replicates. To meet acceptance
criteria, concentrations in at least 2/3 of QC samples should
remain within 715% with accuracy in the range 85–115%.
Dilution integrity was assessed by assay of ﬁve samples with
analyte concentrations above the ULOQ i.e., at 200 ng/mL
and at the HQC level. Six replicates of samples after ten-fold
dilution (20.0 and 3.0 ng/mL) were prepared and their OLZ
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to concentrations obtained from the calibration curve.
2.6. Bioequivalence study design
The design of the study comprised an open label, randomized, two
period, two treatment, two sequence, crossover, balanced, single
dose, evaluation of the relative oral bioavailability of a 5 mg OLZ
disintegrating tablet from a sponsor company (test) and a 5 mg
OLZ disintegrating tablet (ZYPREXAs ZYDISs) from Eli Lilly
and Co., Indianapolis, Indiana 46285, USA (reference) in 40
healthy Indian males under fasting and fed conditions. The study
also included evaluation of a 10 mg OLZ disintegrating tablet
from a Sponsor company (test) and a 10 mg OLZ disintegrating
tablet (ZYPREXAs VELOTABTM) from Eli Lilly and Co.,
Netherlands (reference) in 40 healthy Indian males under fasting
conditions. All participants were informed of the aims and risks of
the study and gave written consent. Inclusion criteria were; age
18–45 years, body mass index 18.5–30.0 kg/height2, and no
abnormalities on general physical examination, electrocardiogram
and laboratory tests (hematology, blood and urine chemistry and
immunological tests). Exclusion criteria were; allergy to OLZ,
alcoholism, smoking, diabetes, psychosis, and any disease which
could compromise the haemopoietic, gastrointestinal, renal, hepa-
tic, cardiovascular, respiratory or central nervous systems. The
protocol was approved and subject to review by the relevant
Institutional Ethics Committee. All procedures in dealing with
human subjects were based on the International Conference on
Harmonization, E6 Good Clinical Practice (ICH, E6 GCP)
guidelines41.
Subjects in fasting studies were required to fast for 10 h
before administration of drug. Subjects in fed studies were
given a high fat, high (969) calorie breakfast (consisting of
200 mL milk with 16 g sugar, 80 g black gram, two slices bread
and butter and two cheese cutlets) 30 min prior to drug
adminstration. Blood samples were collected in vacutainers
containing K2-EDTA anticoagulant before and at 1–10, 12,
16, 24, 36, 48, 72, 96, 120, 144 and 168 h after administration
of drug. Plasma obtained by centrifugation at 1811 g and
4 1C for 15 min was stored at 20 1C until assayed. An
incurred sample reanalysis (ISR) was also conducted for all
three studies by computerized random selection of 442 samples
(10% of the total study sample) with concentrations near the
Cmax or during the elimination phase. The results were
compared with corresponding values obtained earlier for the
same sample using the same procedure. The percent change
should not be more than 720%42 where
Change ð%Þ ¼ ½ðRepeat valueInitial valueÞ=
Mean of repeat and initial values  100% ð1Þ
2.7. Statistical analysis
Pharmacokinetic parameters for OLZ were estimated by non-
compartmental analysis using WinNonlin software version
5.2.1 (Pharsight Corporation, Sunnyvale, CA, USA). The
Cmax values and the time to reach maximum plasma concen-
tration (Tmax) were determined directly from plasma concentra-
tion-time curves. Area under plasma concentration-time curves
from time 0 to 168 h (AUC0–168) was calculated using the linear
trapezoidal rule. AUC0–N was calculated as AUC0–168þCt/kel,where Ct is the last plasma concentration measured and kel is
the elimination rate constant determined by linear regression of
the logarithm linear part of the plasma concentration-time
curve. The T1/2 of OLZ was calculated as ln 2/kel. To determine
whether test and reference formulations were pharmacokineti-
cally bioequivalent, the mean and 90% conﬁdence intervals (CI)
of log transformed Cmax, AUC0–168, AUC0–N and their ratios
(test/reference) were determined using SASs software version
9.1.3 (SAS Institute Inc., Cary, NC, USA). The formulations
were considered bioequivalent if the differences between the
compared parameters were not signiﬁcantly different (PZ0.05)
and the 90% CIs for these parameters fell within the range
0.8–1.25.3. Results and discussion
3.1. Method development
The objective of the present work was to develop and fully
validate an LC-MS/MSmethod for the determination of OLZ
in human plasma with sensitivity adequate to monitor the
concentration of OLZ for least ﬁve half lives after a therapeutic
dose. To realize this aim, the extraction procedure, mass
spectrometry and chromatographic conditions were optimized.
The ESI was operated in the positive ion mode as both OLZ
and IS are basic in nature. OLZ and IS gave predominant,
singly charged protonated precursor [MþH]þ ions at m/z 313.2
and 384.2, respectively in Q1 full scan spectra. Furthermore, the
most abundant ion in the product ion mass spectra of OLZ was
at m/z 256.2, resulting from cleavage of the piperazine ring to
the neutral fragment, CH3NHCH¼CH2. As previously
reported43, other characteristic fragments were observed at
m/z 282.4 and 213.0 attributed to formation of CH3NH2 and
elimination of the piperazine ring, respectively. The proposed
fragmentation pathway of OLZ is depicted in Fig. 2a.
For quetiapine, the most stable and reproducible product
ion at m/z 253.2 arises from cleavage of the piperazine ring44.
The other product ion at m/z 279.4 is due to breaking of two
C–N bonds from the precursor ion to eject the fragment,
(HOCH2CH2OCH2CH2NH2) m/z 105, as shown in Fig. 2b.
To attain an ideal Taylor cone and a better impact on spectral
response, the nebulizer gas (gas 1) pressure was optimized at
55 psi. Fine tuning of the nebulizer and CAD gas was carried
out to obtain a consistent and stable response. Ion spray
voltage and temperature did not affect analyte response
and were maintained at 5500 V and 550 1C, respectively. A
dwell time of 600 ms was found adequate for OLZ and IS and
no cross talk was observed between the MRMs of analyte
and IS.
Chromatographic conditions including mobile phase selection,
ﬂow rate, column type and injection volume were optimized.
Mobile phases containing different ratios (5:95, 10:90, 15:85, 20:80
and 30:70, v/v) of water–methanol/acetonitrile together with either
formic acid, ammonia (0.01–0.005%), ammonium triﬂuoroacetate,
ammonium acetate or ammonium formate buffers in varying
strengths (2–20 mM) at ﬂow rates of 0.5–1.0 mL/min were evalu-
ated. A number of columns including Hypurity C8 (50 mm
4.6 mm, 5 mm), Hypurity cyano (50 mm 4.6 mm, 5 mm), Beta
basic cyano (100 mm 2.1 mm, 5 mm), BDS Hypersil C18
(50 mm 4.6 mm, 5 mm) and ACE 5C18-300 (100 mm 4.6 mm,
5 mm) were also evaluated. Finally it was found that the ACE
Figure 2 Proposed fragmentation pathways for (a) olanzapine and (b) quetiapine.
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0.01% ammonia in 2 mM ammonium formate solution (pH 6.6)
(85:15, v/v) at a ﬂow rate of 0.9 mL/min provided the best
combination of efﬁciency, peak shape and resolution within
3.0 min. Under these conditions, the retention times for OLZ
and IS were 2.36 and 2.05 min, respectively with a reproducibility
for the OLZ retention time (as CV %) of r1.3% for 100
injections on the same column. Capacity factors for OLZ and IS
based on a solvent front of 1.1 min were 0.86 and 1.15, respectively
with a selectivity factor (a) of 0.74. The number of theoretical
plates for OLZ and IS were 660 and 620, respectively with a
resolution factor of 0.9.In terms of the choice of IS, a deuterated analogue is
preferable but was not available. Therefore an atypical
antipsychotic belonging to the same class of dibenzothiaze-
pines was selected in the present work. Quetiapine showed
similar chromatographic behavior and did not affect analyte
recovery, sensitivity or ion suppression.
As part of the investigation into the extraction efﬁciency of
OLZ from plasma, the effect of the anticoagulants K3EDTA,
K2EDTA and Na-heparin was evaluated. Chin et al.
28 exten-
sively studied the potential matrix effects of anticoagulants
and lipemia on an LC-MS/MS assay for OLZ and its
metabolite. As a result, they suggested that K3EDTA and
Figure 3 MRM ion-chromatograms of olanzapine (m/z 313.2-256.2) and quetiapine (IS, m/z 384.2-253.2) in (a) blank plasma
without analyte and IS, (b) blank plasma with IS, (c) blank plasma with olanzapine at the LLOQ with IS and (d) a study sample at Cmax
after administration of a 5 mg dose of olanzapine.
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Consistent with their observation, the best result was obtained
using K2EDTA as anticoagulant.
As is clear from Table 1, both liquid–liquid extraction (LLE)
and solid phase extraction (SPE) have been used to extract
OLZ. In fact, SPE has been successfully carried out on Varian
C8 BondElut12, StepBio C815, Oasis HLB13 and Oasis MCX35
columns. Similarly, LLE using heptane–isoamyl alcohol18,
hexane–dichloromethane20, ethyl acetate-n-hexane–isopropa-
nol23 and diethyl ether–dichloromethane29 has provided quan-
titative recoveries. Nevertheless, LLE sometimes required an
additional back extraction step under acidic conditions to
produce clean extracts20,23. In the present work, protein
precipitation (PP) using methanol and acetonitrile was ﬁrst
evaluated but gave poor recovery and considerable ion suppres-
sion. LLE under alkaline conditions using different solvents
(diethyl ether, n-hexane, dichloromethane, methyl tert-butyl
ether and ethyl acetate) alone and in combination was then
evaluated23,27,29 but, although diethyl ether–dichloromethane
gave promising results, the recovery was not consistent at all
QC levels. As regards the previous use of SPE, Oasis MCX
columns under acidic conditions (citric acid) gave quantitativeTable 2 Intra-batch and inter-batch accuracy and precision for
QC Conc. added
(ng/mL)
Intra-batch
n Mean conc.
found (mg/mL)a
Accuracy (%)
LLOQ 0.10 6 0.10 100.0
LQC 0.30 6 0.28 93.3
MQC-2 3.00 6 2.89 96.3
MQC-1 16.0 6 15.9 99.4
HQC 30.0 6 29.3 97.7
ULOQ 40.0 6 40.8 102.3
n: total number of observations.
CV: coefﬁcient of variation.
aMean of six replicate observations at each concentration.
bMean of 18 replicate observations over three different analytical ru
Table 3 Absolute matrix effect, relative recovery and process ef
QC Aa (CV, %) Bb (CV, %) Cc (CV, %)
LQC 0.0324 (2.00) 0.0318 (0.44) 0.0290 (2.09)
MQC-2 0.3389 (0.65) 0.3317 (2.54) 0.3081 (1.47)
MQC-1 1.9075 (1.23) 1.8637 (3.09) 1.6792 (1.46)
HQC 3.4498 (1.24) 3.4185 (2.29) 3.3059 (1.71)
CV: coefﬁcient of variation.
aMean area ratio response of six replicate samples prepared in mob
bMean area ratio response of six replicate samples prepared by spik
cMean area ratio response of six replicate samples prepared by spik
d(B/A) 100%.
e(C/B) 100%.
f(C/A) 100%¼ (MERE)/100.
gValues for internal standard, quetiapine.recovery of psychotropic drugs and their metabolites28,35 and
Raggi et al.13 obtained a recovery of OLZ of 97.9% using Oasis
HLB under neutral conditions. Accordingly SPE on Oasis
columns with hydrophilic–lipophilic balance (HLB) were eval-
uated under both acidic and neutral conditions and shown to
provide quantitative recovery with minimum matrix effects in
both cases. However, given that a slightly higher recovery was
obtained using an acidic media (100 mL 25% orthophosphoric
acid), the latter conditions were used in the present work.3.2. System suitability and carryover
During assay validation, the precision (CV, %) of a system
suitability test was found to be in the range 0.11–0.54% for
retention time and 1.6–2.2% for the area response of OLZ and
IS. The signal-to-noise ratio for system performance was Z25
for both analyte and IS. Carryover was shown to be negligible
(r0.51%) in that no enhancement in response was observed in
extracted blank plasma (without IS and analyte) after sub-
sequent injection of the ULOQ standard at the retention times
of OLZ or IS.olanzapine.
Inter-batch
CV (%) n Mean conc.
found (mg/mL)b
Accuracy (%) CV (%)
4.3 18 0.10 100.0 4.6
2.3 18 0.29 96.7 2.1
3.2 18 3.00 100.0 3.2
1.1 18 15.7 98.1 2.1
0.6 18 29.8 99.3 1.9
1.9 18 41.1 102.8 2.6
ns.
ﬁciency for olanzapine.
Absolute matrix
effect (ME, %)d
Relative recovery
(RE, %)e
Process efﬁciency
(PE, %)f
98.2 (101.3)g 91.1 (97.5)g 89.5 (98.8)g
97.9 (101.7)g 92.9 (96.4)g 90.9 (98.0)g
97.7 (101.8)g 90.1 (96.9)g 88.0 (98.7)g
99.1 (100.4)g 96.7 (94.1)g 95.8 (94.5)g
ile phase (neat samples).
ing in extracted blank plasma.
ing before extraction.
Table 5 Stability results for olanzapine under different condition
Stability Storage condition L
Bench top stability Room temperature (24 h) L
H
Processed sample stability Auto sampler (4 1C, 97 h) L
(extracted samples) H
Processed sample stability Room temperature (45 h) L
(extracted samples) H
Freeze and thaw stability After 6th cycle at 20 1C L
H
Long term stability 90 days at 20 1C L
H
CV: coefﬁcient of variation.
n: number of replicates at each level.
Change ð%Þ ¼ Meanstability samplesMeancomparison samples
Meancomparison samples
 100%
Figure 4 Representative post column analyte infusion chroma-
tograms for olanzapine and quetiapine (IS). (a) Exact ion current
(XIC) chromatogram of olanzapine (m/z 313.2-256.2) (b) XIC
of quetiapine (m/z 384.2-253.2).
Table 4 Relative matrix effect in different lots of human
plasma at LQC and HQC levels for olanzapine (n¼4).
Plasma lot Mean calculated conc.a (CV, %)
LQC
(0.30 ng/mL)
HQC
(30.0 ng/mL)
Lot-1 0.30 (2.9) 31.8 (0.3)
Lot-2 0.28 (3.6) 31.4 (0.4)
Lot-3 0.31 (2.3) 31.4 (0.6)
Lot-4 0.31 (2.3) 31.8 (1.0)
Lot-5 0.29 (2.8) 32.0 (0.8)
Lot-6 0.31 (0.8) 32.4 (0.8)
Lot-7 (haemolysed) 0.28 (0.5) 30.4 (0.7)
Lot-8 (lipemic) 0.28 (1.2) 30.3 (1.0)
CV: coefﬁcient of variation.
aMean of four replicate observations at each concentration.
LC–MS/MS assay for olanzapine in human plasma 4893.3. Selectivity and interference
All samples were found to be free of interference from endogenous
substances in plasma as shown in Figs. 3a–c. Similarly, no
interference was observed from commonly used medications such
as acetaminophen, aspirin, caffeine, cetirizine, chlorpheniramine
maleate, ibuprofen and pseudoephedrine as shown in Fig. 3d. In
addition, the three antipsychotic drugs (clozapine, risperidone and
aripiprazole) did not interfere in the determination of OLZ. This
was because, although their retention times were 2.72, 2.60 and
3.21 min, respectively, their MRM transitions were different from
that of OLZ. Accuracy (%) for OLZ at all QC levels was in the
range 93.4–101.4%.3.4. Linearity, sensitivity, accuracy and precision
All six calibration curves were linear over the concentration range
0.10–40.0 ng/mL with correlation coefﬁcients rZ0.9996. The
equation of the calibration curve was y¼ (0.119670.0106)x
(0.000770.0001) where y is analyte/IS peak area ratio and x is
analyte concentration. Accuracy (%) and precision (CV, %) of
calibration standards were 97.0–103.1% and 1.2–3.9%, respec-
tively. The LLOQ was 0.10 ng/mL at a signal-to-noise ratio Z25
and the limit of detection (LOD) was 0.012 ng/mL.
Intra-day precision and accuracy (Table 2) were 0.6–4.3%
and 93.3–102.3%, respectively. Inter-day precision and accu-
racy were 1.9–4.6% and 96.7–102.8%, respectively.3.5. Recovery and matrix effects
The relative recoveries, absolute matrix effects and process
efﬁciencies for OLZ and IS are presented in Table 3. The relative
recovery of analyte is the ‘‘true recovery’’ since it is calculated by
comparing the response (analyte/IS) of samples spiked before
extraction with the response of samples spiked after extraction.
The process efﬁciency/absolute recovery obtained for OLZ and
IS was Z88% at all QC levels. Furthermore, relative matrix
effects which compares the precision (CV, %) between different
lots of plasma samples spiked after extraction varied from 0.3 to
3.6% for OLZ at the LOQ and HQC levels (Table 4). Post-
column analyte infusion chromatograms (Fig. 4) indicate theres (n¼6).
evel Mean stability
sample (mg/mL)
CV (%) Change (%)
QC 0.28 1.9 6.7
QC 29.1 0.5 3.0
QC 0.29 2.7 3.3
QC 29.7 0.9 1.0
QC 0.30 7.6 0.0
QC 29.5 0.6 1.7
QC 0.29 1.4 3.3
QC 29.5 0.6 1.7
QC 0.28 3.7 6.7
QC 28.4 2.7 5.3
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Table 6 Summary of mean pharmacokinetic parameters for bioequivalence studies with olanzapine in healthy volunteers.
Formulation and dose strength Study condition; No. of
subjects; wash out period;
measurement time period
Cmax7SD (ng/mL) Tmax7SD (h) AUC0–t7SD (ng.h/mL)/
AUC0–N7SD (ng.h/mL)
t1/27SD (h)/
Kel7SD (1/h)
Ref
T R T R T R T R
Ta-10 mg OLZ tablet, Integrols, Rb-10 mg OLZ tablet, Zyprexas Fasting; 24 male subjects;
14 days; 0–72 h
13.0774.47 11.6074.08 6.0472.77 6.4274.04 363.387129.28/
466.877165.38
367.267119.22/
477.987137.38
30.5079.15/
0.0270.01
32.66711.34/
0.0270.01
45
Tc-10 mg OLZ tablet, Rd-10 mg OLZ tablet, Zyprexas VelotabTM Fasting; 40 Indian male
subjectsf; 21 days; 0–168 h
11.9273.35 10.877 2.44 5.8172.27 5.5871.96 473.147134.57/
494.787146.06
445.317117.10/
474.747126.81
36.2676.38/
0.0270.003
34.3875.42/
0.0270.004
PW
Tc-5 mg OLZ tablet, Re-5 mg OLZ tablet, Zyprexas Zydiss Fasting; 40 Indian male
subjectsf; 21 days; 0–168 h
5.0271.59 4.9871.36 8.2371.40 7.9071.67 204.19746.33/
213.55748.42
206.45747.56/
215.57747.73
35.6376.94/
0.0270.005
35.86714.29/
0.0270.004
PW
Tc-5 mg OLZ tablet, Re-5 mg OLZ tablet, Zyprexas Zydiss Fed; 40 Indian male
subjectsf; 21 days; 0–168 h
5.0571.14 4.9771.26 8.0071.82 7.4771.91 214.36754.50/
223.49756.47
212.22758.14/
221.81761.41
35.3477.05/
0.0270.004
35.3176.14/
0.0270.003
PW
T, test formulation; R, reference formulation; OLZ, olanzapine; SD, standard deviation.
Cmax, maximum plasma concentration; Tmax, time point of maximum plasma concentration; T1/2, half life of drug elimination during the terminal phase; AUC0t: area under the plasma
concentration-time curve from zero hour to 168 h; AUC0N: area under the plasma concentration-time curve from zero hour to inﬁnity; PW, present work.
aGlobal Napi Pharmaceuticals, Cairo, Egypt.
bEli Lilly and Company, Basingstoke, Hampshire, United Kingdom.
cOrally disintegrating tablets from a Sponsor company.
dOrally disintegrating tablets from Eli Lilly and Company, Netherland.
eOrally disintegrating tablets from Eli Lilly and Company, Indianapolis, USA.
fIn the age group of 18–45 years and having body mass index between 18.5 and 30.0 kg/height2.
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LC–MS/MS assay for olanzapine in human plasma 491OLZ in extracted plasma samples was stable for 45 h at room
temperature and for 97 h at 4 1C. OLZ was stable in plasma
stored at 20 1C for a minimum of 90 days. The values of
percent changes for all stability experiments are compiled in
Table 5.
The precisions for ten-fold dilutions of 5ULOQ (20.0 ng/mL)
and HQC (3.00 ng/mL) were 0.5 and 1.2%, respectively with
accuracies of 101.6 and 103.2%, respectively. These values are
within the acceptance limits of 15% for precision and 85–115%
for accuracy.
Method ruggedness was evaluated for QC samples by (a)
reanalysis on a different column of the same make and (b)
reanalysis by a different analyst. Precision (CV, %) and
accuracy (%) for reanalysis on different columns were in the
ranges 1.6–2.8% and 94.9–99.2%, respectively. Corresponding
ranges for reanalysis by a different analyst were 1.9–3.2% and
95.8–101.6%, respectively.Figure 6 Graphical representation of the results for 160 incurred
sample reanalyses of olanzapine.3.7. Bioequivalence study
All subjects completed the studies with no evidence of adverse
events. Fig. 5 shows plasma concentration-time proﬁles of OLZ
in healthy subjects under fasting and fed conditions. The
method allowed plasma concentrations to be monitored for
up to 168 h. In total, 6183 samples were successfully analyzed
with precision and accuracy within acceptable limits. Table 6
compares pharmacokinetic parameters for the 10 mg tablet with
values reported in a similar study45. Cmax and Tmax values were
marginally lower than in the previous study while AUC0–t,
AUC0–N and T1/2 values were somewhat higher. This may be
due to differences in genetics, race, age and gender (body size
and muscle mass) of the study subjects or to differences in the
type of food consumed. The effect of food was negligible in the
study of the 5 mg tablet. Comparison of the two dose strengths
(5 and 10 mg) reveals dose-dependent pharmacokinetics. The
bioequivalence statistics of the two formulations are summar-
ized in Table 7. No statistically signiﬁcant differences were
found in any parameter between the two formulations. The
mean log-transformed ratios of the parameters and their
90% CIs were all within the required ranges conﬁrming the
bioequivalence of the test and reference products. The percent
change in the randomly selected samples for incurred sample
(assay reproducibility) reanalysis (Fig. 6) was in the rangeTable 7 Comparison of treatment ratios and 90% CIs of n
olanzapine test and reference formulations under fasting and fed c
Dose Parameter Ratio (test/reference, %) 90
Fast Fed F
5 mg Ln Cmax (ng/mL) 100.3 102.3 9
Ln AUC0–168 (h  ng/mL) 99.1 101.5 9
Ln AUC0–N (h  ng/mL) 99.1 101.4 9
10 mg Ln Cmax (ng/mL) 108.5 – 10
Ln AUC0–168 (h  ng/mL) 103.4 – 9
Ln AUC0–N (h  ng/mL) 103.6 – 9
CI: conﬁdence interval; CV: coefﬁcient of variation.7.43 to 8.07%. This authenticates the reproducibility and
ruggedness of the method.
3.8. Comparison with previous methods
The method reported here has high sensitivity with the use of
only 200 mL plasma samples. Moreover, the total analysis time
(including extraction and chromatography) is the shortest of
all reported methods except one29. Also, the on-column
loading of OLZ at the ULOQ is only 50 pg/injection which
is about 12 times lower than for the equally sensitive method
reported by Nirogi et al.29. Additionally, the bioequivalence
study was conducted in both fasting and fed conditions.
Incurred sample reanalysis, which has now become mandatory
for clinical and non-clinical studies proves the reproducibility
of the proposed method in samples from healthy subjects. A
detailed comparison of the salient features of the present
method with those of reported asays for OLZ in human
plasma is given in Table 8.4. Conclusions
The objective of this work was to develop a selective and
sensitive method for the determination of olanzapine in
human plasma suitable for pharmacokinetic studies. The
method was shown to be free of interference from other
antipsychotic drugs namely clozapine, risperidone and aripi-
prazole and from other commonly used medications. More-
over, the sensitivity was sufﬁcient to monitor olanzapine
plasma concentration for at least ﬁve half lives after a
therapeutic dose with good intra- and inter-day accuracy
and precision. In fact, the maximum on-column loading wasatural log(Ln)-transformed parameters for 5 mg and 10 mg
ondition.
% CI (Lower–Upper) Power Intra subject
variation (CV, %)
ast Fed Fast Fed Fast Fed
6.7–104.1 97.2–107.7 1.00 1.00 9.7 12.9
6.0–102.3 97.4–105.7 1.00 1.00 8.4 10.3
5.9–102.4 97.1–105.8 1.00 1.00 8.6 10.7
2.6–114.9 – 1.00 – 14.3 –
8.2–108.8 – 1.00 – 13.0 –
8.5–109.0 – 1.00 – 12.8 –
Table 8 Comparison of salient features of the present method with reported procedures for olanzapine in human plasma.
No. Lower limit of
quantitation
(ng/mL)
Plasma
volume for
processing
(mL)
Retention time; run time;
maximum on-column loading at
ULOQ per injection volume
Organic solvent
consumption
(extraction and
chromatography)
per sample
analysis (mL)
Post-column
infusion study;
relative matrix
effect results (%
CV)
Incurred
sample
reanalysis
results
Ref.
1a 5.0 500 6.1 min; 15.0 min; 3.0 ng 6.0 NA NA 15
2a 0.4 250 4.2 min; 8.0 min; 0.8 ng 7.0 NA NA 16
3 1.0 1000 8.0 min; 15.0 min; 3.3 mg 10.5 NA NA 18
4 2.0 1000 5.4 min; 12.0 min; 60 ng 12.0 NA NA 20
5b 0.5 1000 6.24 min; 20.0 min; – 12.4 NA NA 23
6c 1.0 500 5.84 min; 10.0 min; 2.5 ng 6.0 Yes; NA NA 27
7 0.1 500 1.0 min; 2.0 min; 0.6 ng 5.5 Yes; NA NA 29
8d 2.0 500 8.1 min; 14.0 min; 2.0 ng 5.0 NA NA 35
9 0.1 200 2.36 min; 3.5 min; 0.05 ng 4.5 Yes; 0.3% to 3.6%
for 8 lots of plasma
Change (%)
from 7.43
to 8.07%
PM
ULOQ: upper limit of quantitation.
NA: data not available.
PM: present method.
aAlong with its metabolite desmethylolanzapine.
bAlong with clozapine, N-desmethylclozapine, quetiapine and perazine.
cAlong with clozapine, risperidone and quetiapine.
dAlong with aripiprazole, atomoxetine, duloxetine, clozapine, sertindole, venlafaxine and their active metabolites dehydroaripiprazole,
norclozapine, dehydrosertindole and O-desmethylvenlafaxine.
Dinesh Somabhai Patel et al.492considerably less than in other reported procedures which
contributes to maintaining the efﬁciency and life of the
column. Finally the simplicity of sample preparation and the
short chromatographic run time of 3.5 min gives the method
the capability for high sample throughput. The proposed
method provides the means to carry out a wide range of
pharmacokinetic/bioequivalence studies.
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